Gapping up
In reaction to earnings/guidance: ECOM +19.4%, WTW +18.7%, STMP +18.5%, VRNS +17.7%, FNGN +17.6%, SREV +16.9%, UBNT +16.8%, LPTH +16.7%, DATA +16.2%, QRVO +15.4%, RATE +15%, YUME +12.9%, AXGN +12.5%, MITK +10.5%, TRUE +10.4%, AIRM +10.1%, KTOS +9.8%, NVDA +9.7%, SXE +9.7%, BLDR +9.7%, DWA +9.6%, RPTP +9.4%, PODD +8.8%, MNST +8.3%, OLED +7.7%, TTI+7.4%, AGTC +6.9%, SHAK +6.8%, OCLS +6.6%, BCEI +6.6%, ICUI +5.7%, WING +5.5%, PCTY +5.5%, ELON +4.8%, AEZS +4.6%, MSCC +4.5%, VTL +4.5%, CYTX +4.4%, AEE +4.4%, SWKS +4.3%, ANET +3.7%, TTWO +3.6%, GSVC +3.4%, ABTL +3.2%, ABCO +3.2%, GERN +3%, ETM +2.7%, ERII +2.4%, CBI +2.1%, JOE +2%, CYBR +1.8%, AL +1.6%, NKTR +1.5%, SEMG +1.4%, BETR +1.3%, PBA+1.3%, ACHN +1.2%, CSOD +1.1%, MDVN +1%, RBA +1%
M&A news: ZSPH +40.8% (to be acquired by AstraZeneca (AZN) for $90/share, or ~$2.7 bln), LXRX +30% (Lexicon Pharma and Sanofi (SNY) set up collaboration on sotagliflozin), YOKU +10.1% (to be acquired by Alibaba Group Holding Limited (BABA) for $27.60/ADS share in cash), RLYP +6.7% (ZSPH peer)
Other news: PVCT +28.7% (reported results that reveal a clinically relevant immunoadjuvant pathway triggered by tumor cell death secondary to ablation with RB), MHR +23.3% (reported refinancing of its existing senior secured revolving credit facility), SHAK +7.1% (still checking), AGEN +4.4% (Agenus enters into three transactions, including agreement to acquire XOMA's (XOMA) antibody pilot plant manufacturing facility and capabilities ), CLLS +4.2% (FT discusses benefits and possible success of cancer genetic therapy), BLUE +4.1% (slightly rebounding following recent weakness), VRX +3.2% (Pershing Square Holdings releases complete communication sent from Bill Ackman to Valeant Pharm'a (VRX) CEO), MNKD +2.9% (still checking), MOMO +2.7% (still checking), OXGN +2.4% (reports initial data from a Phase 1b/2 study of CA4P in combination with Votrient; results are 'encouraging and we expect to move into the phase 2 portion of the study in early 2016' ), .
Analyst comments: WM +0.9% (initiated with a Outperform at Credit Suisse)
.
In reaction to earnings/guidance: ECOM +19.4%, WTW +18.7%, STMP +18.5%, VRNS +17.7%, FNGN +17.6%, SREV +16.9%, UBNT +16.8%, LPTH +16.7%, DATA +16.2%, QRVO +15.4%, RATE +15%, YUME +12.9%, AXGN +12.5%, MITK +10.5%, TRUE +10.4%, AIRM +10.1%, KTOS +9.8%, NVDA +9.7%, SXE +9.7%, BLDR +9.7%, DWA +9.6%, RPTP +9.4%, PODD +8.8%, MNST +8.3%, OLED +7.7%, TTI+7.4%, AGTC +6.9%, SHAK +6.8%, OCLS +6.6%, BCEI +6.6%, ICUI +5.7%, WING +5.5%, PCTY +5.5%, ELON +4.8%, AEZS +4.6%, MSCC +4.5%, VTL +4.5%, CYTX +4.4%, AEE +4.4%, SWKS +4.3%, ANET +3.7%, TTWO +3.6%, GSVC +3.4%, ABTL +3.2%, ABCO +3.2%, GERN +3%, ETM +2.7%, ERII +2.4%, CBI +2.1%, JOE +2%, CYBR +1.8%, AL +1.6%, NKTR +1.5%, SEMG +1.4%, BETR +1.3%, PBA+1.3%, ACHN +1.2%, CSOD +1.1%, MDVN +1%, RBA +1%
M&A news: ZSPH +40.8% (to be acquired by AstraZeneca (AZN) for $90/share, or ~$2.7 bln), LXRX +30% (Lexicon Pharma and Sanofi (SNY) set up collaboration on sotagliflozin), YOKU +10.1% (to be acquired by Alibaba Group Holding Limited (BABA) for $27.60/ADS share in cash), RLYP +6.7% (ZSPH peer)
Other news: PVCT +28.7% (reported results that reveal a clinically relevant immunoadjuvant pathway triggered by tumor cell death secondary to ablation with RB), MHR +23.3% (reported refinancing of its existing senior secured revolving credit facility), SHAK +7.1% (still checking), AGEN +4.4% (Agenus enters into three transactions, including agreement to acquire XOMA's (XOMA) antibody pilot plant manufacturing facility and capabilities ), CLLS +4.2% (FT discusses benefits and possible success of cancer genetic therapy), BLUE +4.1% (slightly rebounding following recent weakness), VRX +3.2% (Pershing Square Holdings releases complete communication sent from Bill Ackman to Valeant Pharm'a (VRX) CEO), MNKD +2.9% (still checking), MOMO +2.7% (still checking), OXGN +2.4% (reports initial data from a Phase 1b/2 study of CA4P in combination with Votrient; results are 'encouraging and we expect to move into the phase 2 portion of the study in early 2016' ), .
Analyst comments: WM +0.9% (initiated with a Outperform at Credit Suisse)
.